Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03506854 · ClinicalTrials.gov registry record · Phase 1
Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
A Phase 1 study, sponsored by Akcea Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03506854 is a Phase 1 study that has completed, run by Akcea Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT03506854, a Phase 1 study, has completed, sponsored by Akcea Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study of ISIS 681257 Subcutaneous Injections in Male And Female Subjects with Normal and Impaired Renal Function
Interventions
- DRUG ISIS 681257
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2018-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03506854
The ClinicalTrials.gov registry entry for NCT03506854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akcea Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 681257 is the first listed.
NCT03506854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03506854 about?
NCT03506854 is a clinical study titled "Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients". This is a Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study of ISIS 681257 Subcutaneous Injections in Male And Female Subjects with Normal and Impaired Renal Function
What is the current status of trial NCT03506854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-03-20. Estimated completion is 2018-10-11.
What interventions are being tested in trial NCT03506854?
The interventions under investigation include: ISIS 681257 (DRUG).
Who is sponsoring clinical trial NCT03506854?
This trial is sponsored by Akcea Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.